Navigation Links
VIVUS to Present at the Credit Suisse 2011 Healthcare Conference
Date:11/3/2011

MOUNTAIN VIEW, Calif., Nov. 3, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Credit Suisse 2011 Healthcare Conference.

The VIVUS presentation will take place at the Arizona Biltmore Hotel in Phoenix, AZ on Thursday, November 10, 2011 at 9:30 a.m. MST.  A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, Qnexa®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial Qnexa NDA on October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction, with an FDA action date of April 29, 2012. For more information about the company, please visit www.vivus.com.

 CONTACT: 

  

 

 VIVUS, Inc. Investor Relations:The Trout Group 

 

 Timothy E. Morris 

Brian KorbChief Financial Officer 

bkorb@troutgroup.com 

 

 650-934-52 

646-378-2923   
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. VIVUS Resubmits Qnexa NDA to the FDA
2. VIVUS Provides Regulatory Update on QNEXA
3. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
4. VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock
5. VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
6. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
7. VIVUS to Present at Three Upcoming Investor Conferences in March
8. VIVUS Provides Regulatory Update on QNEXA NDA
9. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
10. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
11. VIVUS to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... development of Physiocrine-based therapeutics to address severe, rare diseases, today announced ... upcoming BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay ... December 14, 2016, at 4:20 p.m. ET. About ... ...
(Date:12/9/2016)... , Dec. 9, 2016  Forge Therapeutics, ... AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) ... ,LpxC, for the treatment of bacterial infections including ... been recognized as an attractive antibacterial target for ... lack of suitable chemical starting points has hampered ...
(Date:12/8/2016)... 8, 2016  The global biosurgery market is expected ... forecast period of 2016 to 2021. The market is ... USD 18.21 billion in 2016. The market is primarily ... sports related injuries and spinal problems, increasing clearance of ... effective blood loss management. In this report, ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... 2016 , ... MEDI+SIGN®, a provider of fully-automated patient monitoring ... for Emergency Departments (ED) has been added to their portfolio. Housed in a ... and with a simplified pallet of information available to the patient, the Digital ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Compensation Research Institute (WCRI) officially opened registration today for its 33rd Annual ... in Boston, MA . , The theme of the conference is “Persistent Challenges ...
(Date:12/8/2016)... ... 2016 , ... CURE Media Group, the nation’s leading digital and print media ... Lung Cancer in efforts to combat lung cancer, announced CURE Media Group President Michael ... Media Group is honored to team up with Upstage Lung Cancer in order to ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... version gives development continuity to its innovative Unified Instance Manager architecture, meeting ... In addition, this new version optimizes the unattended auto-dialing system without agents, ...
(Date:12/8/2016)... Peachtree City, Ga (PRWEB) , ... December 08, ... ... and moving as soon after surgery as possible. With this in mind, SIGVARIS ... vein thrombosis (DVT or blood clot) during bed rest and provide the benefits ...
Breaking Medicine News(10 mins):